Wendi Haller
Family · Louisville, KYNPI 1184026205
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 92.3% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2023 at $11,025 and has fallen 99.2% since, to $89 in 2025. Among family clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 165 payments — averaging $198.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$30K
- United Therapeutics Corporation$909
- Pfizer$542
- Insmed, Inc.$230
- Actelion Pharmaceuticals US, Inc.$117
- GSK$101
- plus $614 from 20 others
Across 1 payment — averaging $958.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$958
What the payments were for
- Consulting fees$2,1847%
- Speaking & faculty fees$18,55557%
- Travel & lodging$8,41426%
- Food & beverage$3,65211%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 70 | $30,294 |
| United Therapeutics Corporation | 6 | $909 |
| Pfizer | 30 | $542 |
| Insmed, Inc. | 11 | $230 |
| Actelion Pharmaceuticals US, Inc. | 6 | $117 |
| GSK | 7 | $101 |
| Mylan Specialty L.p. | 5 | $83 |
| Grifols USA, LLC | 4 | $79 |
| Johnson & Johnson | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Sanofi | 2 | $44 |
| Mallinckrodt Hospital Products Inc. | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Jazz Pharmaceuticals Inc. | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Bayer | 1 | $24 |
| Genentech USA, Inc. | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Chiesi USA, Inc. | 1 | $16 |
| Baxter Healthcare | 1 | $15 |
| Ambu Inc. | 1 | $15 |
| Fisher & Paykel Healthcare Inc | 1 | $14 |
| Merck | 1 | $14 |
| CSL Behring | 1 | $13 |
| Electromed, Inc. | 1 | $13 |
| AstraZeneca | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,807 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $11,165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $101 | $11,16519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.
Other family in Louisville
- Smita RanjanLouisville$92K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Shelley WaldmanLouisville$59K
- Esther MuhsLouisville$44K
- Barbra CaveLouisville$41K
- Kayla WilsonLouisville$40K
- Christin ThompsonLouisville$38K
- Tracy GowanLouisville$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.